Correction of residual hyperopia using light adjustable IOL technology

Article

Correction of residual hyperopia using light adjustable IOL technology

Correction of residual hyperopia using light adjustable IOL technology, from the Febraury 18 issue of the American Journal of Ophthalmology.

Please click here to read the abstract.

Recent Videos
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
Related Content
Planet Earth, made up of pixels, on orange and blue futuristic background. Some of the pixels are flying into space to represent data being transmitted globally. Image credit: ©vit_mar – stock.adobe.com

Crafting an international database for retinopathy of prematurity

Hattie Hayes;Caroline Catt, MB, BS, FRANZCO
February 5th 2025
Article

Intercontinental collaboration is key to unlocking ROP in our lifetime

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person in a suit sits at a laptop. A US Food and Drug Administration logo and approval badge are superimposed over the image. Image credit: ©Nirusmee – stock.adobe.com

US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema

Martin David Harp
February 4th 2025
Article

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An illustrated eyeball inside a DNA helix. Image credit: ©Adisak – stock.adobe.com

Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy

Grace Koennecke
February 3rd 2025
Article

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.